Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy

Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy

Despite recent advances in oncology, diagnosis, and therapy, treatment of pancreatic ductal adenocarcinoma (PDAC) is still exceedingly challenging. PDAC remains the fourth leading cause of cancer-related deaths worldwide. Poor prognosis is due to the aggressive growth behavior with early invasion an...

Full description

Bibliographic Details
Main Authors: Anna-Laura Kretz, Silvia von Karstedt, Andreas Hillenbrand, Doris Henne-Bruns, Uwe Knippschild, Anna Trauzold, Johannes Lemke
Format: Article
Language:English
Published: MDPI AG 2018-03-01
Series:Cancers
Subjects:
TRAIL
pancreatic adenocarcinoma
TRAIL-R agonists
Online Access:http://www.mdpi.com/2072-6694/10/3/77

Similar Items

Similar Items